Precision Medicine in Hormone Receptor-Positive Breast Cancer

Overview

Journal Front Oncol

Specialty Oncology

Date 2018 May 22

PMID 29780747

Citations 18

Authors

Azadeh Nasrazadani

Roby A Thomas

Steffi Oesterreich

Adrian V Lee

Affiliations

Soon will be listed here.

Abstract

In recent decades, breast cancer has become largely manageable due to successes with hormone receptor targeting. Hormone receptor-positive tumors have favorable outcomes in comparison to estrogen receptor (ESR1, ER)/progesterone receptor-negative tumors given the targetable nature of these tumors, as well as their inherently less aggressive character. Nonetheless, treatment resistance is frequently encountered due to a variety of mechanisms, including mutations and loss of ER expression. A new era of precision medicine utilizes a range of methodologies to allow real-time analysis of individual genomic signatures in metastases and liquid biopsies with the goal of finding clinically actionable targets. Preliminary studies have shown improved progression-free survival and overall survival with implementation of this information for clinical decision making. In this review, we will discuss the opportunities and challenges in integrating precision medicine through next-generation genomic sequencing into the management of breast cancer.

Citing Articles

A Micro-Computed Tomography-Based Simplified Approach to Measure Body Composition, Osteoporosis, and Lung Fibrosis in Mice.

Landau M, Zou B, Yang Z, Rowan B, Anbalagan M Bio Protoc. 2025; 15(4):e5207.

PMID: 40028031 PMC: 11865830. DOI: 10.21769/BioProtoc.5207.

The management of locally advanced, ulcerated breast cancer in a menopausal woman: a case report.

Izzo P, Izzo L, Polistena A, Sibio S, Codacci-Pisanelli M, Crocetti D Ann Med Surg (Lond). 2023; 85(10):5176-5178.

PMID: 37811082 PMC: 10553047. DOI: 10.1097/MS9.0000000000001187.

Tamoxifen Response at Single Cell Resolution in Estrogen Receptor-Positive Primary Human Breast Tumors.

Kim H, Whitman A, Wisniewska K, Kakati R, Garcia-Recio S, Calhoun B bioRxiv. 2023; .

PMID: 37066379 PMC: 10103953. DOI: 10.1101/2023.04.01.535159.

Structure-Based Profiling of Potential Phytomolecules with AKT1 a Key Cancer Drug Target.

Mirza Z, Karim S Molecules. 2023; 28(6).

PMID: 36985568 PMC: 10051420. DOI: 10.3390/molecules28062597.

Listening to the Patient: Improving the Design and Conduct of Clinical Trials in Inflammatory Bowel Diseases.

Sharp D, Ringer S, Park K, Tole S, Rubin D, Regueiro M Crohns Colitis 360. 2023; 2(1):otaa011.

PMID: 36777962 PMC: 9802181. DOI: 10.1093/crocol/otaa011.

References

Toy W, Shen Y, Won H, Green B, Sakr R, Will M . ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet. 2013; 45(12):1439-45. PMC: 3903423. DOI: 10.1038/ng.2822. View

Cristofanilli M, Budd G, Ellis M, Stopeck A, Matera J, Miller M . Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004; 351(8):781-91. DOI: 10.1056/NEJMoa040766. View

Hertz D, Kidwell K, Hilsenbeck S, Oesterreich S, Osborne C, Philips S . CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study. Breast Cancer Res Treat. 2017; 166(1):277-287. PMC: 6028015. DOI: 10.1007/s10549-017-4400-8. View

Burstein H, Temin S, Anderson H, Buchholz T, Davidson N, Gelmon K . Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update. J Clin Oncol. 2014; 32(21):2255-69. PMC: 4876310. DOI: 10.1200/JCO.2013.54.2258. View

Robertson J, Bondarenko I, Trishkina E, Dvorkin M, Panasci L, Manikhas A . Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet. 2016; 388(10063):2997-3005. DOI: 10.1016/S0140-6736(16)32389-3. View

Bronkhorst A, Wentzel J, Aucamp J, van Dyk E, du Plessis L, Pretorius P . Characterization of the cell-free DNA released by cultured cancer cells. Biochim Biophys Acta. 2015; 1863(1):157-65. DOI: 10.1016/j.bbamcr.2015.10.022. View

Murphy C, Dickler M . The Role of CDK4/6 Inhibition in Breast Cancer. Oncologist. 2015; 20(5):483-90. PMC: 4425391. DOI: 10.1634/theoncologist.2014-0443. View

Senkus E, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rutgers E . Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015; 26 Suppl 5:v8-30. DOI: 10.1093/annonc/mdv298. View

Tsimberidou A, Hong D, Ye Y, Cartwright C, Wheler J, Falchook G . Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine Study. JCO Precis Oncol. 2017; 2017. PMC: 5659750. DOI: 10.1200/PO.17.00002. View

10.

Liu Q, Sommer S . Pyrophosphorolysis-activated polymerization (PAP): application to allele-specific amplification. Biotechniques. 2000; 29(5):1072-6, 1078, 1080 passim. DOI: 10.2144/00295rr03. View

11.

Slamon D, Clark G, Wong S, Levin W, Ullrich A, McGuire W . Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235(4785):177-82. DOI: 10.1126/science.3798106. View

12.

Dawson S, Tsui D, Murtaza M, Biggs H, Rueda O, Chin S . Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 2013; 368(13):1199-209. DOI: 10.1056/NEJMoa1213261. View

13.

Khagi Y, Goodman A, Daniels G, Patel S, Sacco A, Randall J . Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor-Based Immunotherapy. Clin Cancer Res. 2017; 23(19):5729-5736. PMC: 5678984. DOI: 10.1158/1078-0432.CCR-17-1439. View

14.

Coates A, Winer E, Goldhirsch A, Gelber R, Gnant M, Piccart-Gebhart M . Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol. 2015; 26(8):1533-46. PMC: 4511219. DOI: 10.1093/annonc/mdv221. View

15.

Quirke V . Tamoxifen from Failed Contraceptive Pill to Best-Selling Breast Cancer Medicine: A Case-Study in Pharmaceutical Innovation. Front Pharmacol. 2017; 8:620. PMC: 5600945. DOI: 10.3389/fphar.2017.00620. View

16.

Barnes D, Millis R, Gillett C, Ryder K, Skilton D, Fentiman I . The interaction of oestrogen receptor status and pathological features with adjuvant treatment in relation to survival in patients with operable breast cancer: a retrospective study of 2660 patients. Endocr Relat Cancer. 2004; 11(1):85-96. DOI: 10.1677/erc.0.0110085. View

17.

Magnani L, Frige G, Gadaleta R, Corleone G, Fabris S, Kempe M . Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer. Nat Genet. 2017; 49(3):444-450. PMC: 5326683. DOI: 10.1038/ng.3773. View

18.

Helissey C, Berger F, Cottu P, Dieras V, Mignot L, Servois V . Circulating tumor cell thresholds and survival scores in advanced metastatic breast cancer: the observational step of the CirCe01 phase III trial. Cancer Lett. 2015; 360(2):213-8. DOI: 10.1016/j.canlet.2015.02.010. View

19.

Lefebvre C, Bachelot T, Filleron T, Pedrero M, Campone M, Soria J . Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis. PLoS Med. 2016; 13(12):e1002201. PMC: 5189935. DOI: 10.1371/journal.pmed.1002201. View

20.

Chan A, Delaloge S, Holmes F, Moy B, Iwata H, Harvey V . Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2016; 17(3):367-377. DOI: 10.1016/S1470-2045(15)00551-3. View